Futura Medical PLC has announced its Annual General Meeting (AGM) to be held on June 20, 2024, at the offices of Liberum Capital Limited in London. Shareholders are encouraged to cast their votes through various methods, including online and in person. The company has also made arrangements for shareholders to listen to the proceedings remotely. The Annual Report and accounts for the year ended December 31, 2023, are available on the company's website.
Futura Medical PLC is a consumer healthcare company specializing in the development and global commercialization of innovative and clinically proven sexual health products. Their lead product, Eroxon, is a topical gel treatment for Erectile Dysfunction (ED) that helps men achieve an erection in ten minutes. ED affects a significant portion of the male population globally, and Eroxon addresses significant unmet needs in the ED market.
The company's core strength lies in its research, development, and commercialization of topically delivered gel formulations in sexual health products. Futura Medical PLC aims to address the unmet needs in the ED market and provide effective solutions for men experiencing ED across all adult age brackets.